Whether you're sourcing suppliers or finding providers, start your journey with confidence today.
Dihexa (N-Hexanoic-Tyr-Ile-(6)-Aminohexanoic Amide)
Also known as: N-hexanoyl-Tyr-Ile-(6)-aminohexanoic amide
Confidence
Updated 2026-03-18
Dihexa is a small peptide-derived compound developed at Washington State University that acts as a potent hepatocyte growth factor (HGF) receptor (c-Met) agonist. In preclinical studies, it demonstrated cognitive-enhancing effects up to 10 million times more potent than BDNF in promoting synaptic connectivity. It is one of the most discussed compounds in nootropic communities, though human data is essentially absent.
Class
Nootropic / Cognitive Enhancer
Routes
Oral, Subcutaneous, Intranasal, Topical
Half-Life
Not established in humans. Estimated hours based on structural analogs.
Dihexa binds to and stabilizes hepatocyte growth factor (HGF), preventing its degradation and enhancing c-Met receptor activation. This promotes synaptogenesis, neuronal survival, and dendritic spine formation. The HGF/c-Met pathway is crucial for neural development, repair, and synaptic plasticity. Dihexa crosses the blood-brain barrier and is orally bioavailable.
Half-Life
Not established in humans. Estimated hours based on structural analogs.
Bioavailability
Oral bioavailability reported in animal models; not quantified in humans.
No approved indications. Research: cognitive enhancement, Alzheimer's disease (preclinical), traumatic brain injury recovery, synaptogenesis.
Published preclinical data from WSU demonstrates dramatic cognitive enhancement in aged rats, restoration of cognitive function in scopolamine-impaired animals, and potent synaptogenic activity. No human clinical trials have been conducted. The extraordinary potency claims (10 million times BDNF) are based on in vitro synaptogenesis assays — clinical relevance unknown. Several patents filed.
Human Studies
0
Animal Studies
10
No human safety data. HGF/c-Met pathway is involved in cancer progression — chronic activation could theoretically promote tumor growth or metastasis. This is a serious theoretical concern that has not been addressed in long-term studies. Use in humans is purely speculative and carries unknown risks.
Investigational. Preclinical only. No IND filed. Sold by research chemical suppliers. Significant safety unknowns.
Drug Interactions: Unknown. Theoretical interactions with c-Met inhibitors (cancer drugs). Monitoring: No established parameters. Research Gaps: Zero human data. Cancer safety concern with HGF/c-Met activation is unaddressed. Pharmacokinetics, dosing, and safety profile entirely unstudied in humans.
Oral/Sublingual/Intranasal (research context only)
Common Range
10–40 mg (oral, extrapolated from animal doses — NOT validated in humans)
Timing
Morning
Frequency
Daily
Cycling
Unknown — no human protocols exist
Important Note
NOT FDA-approved. NO human clinical data. Cancer risk concerns with HGF/c-Met activation. Extreme caution warranted. Research compound only.
Connect with a verified provider offering Dihexa therapy near you.
Nootropic / Neuroprotective Peptide
Semax is a synthetic heptapeptide analog of ACTH(4-10) developed at the Institute of Molecular Genetics in Russia. It is approved in Russia and several CIS countries as a nootropic and neuroprotective agent for stroke recovery, cognitive enhancement, and optic nerve disease. Unlike full-length ACTH, it has no corticosteroid-stimulating activity.
Nootropic / Anxiolytic Peptide
Selank is a synthetic heptapeptide derived from the endogenous immunomodulatory peptide tuftsin, with an added Pro-Gly-Pro sequence for stability. Developed at the Institute of Molecular Genetics (Russian Academy of Sciences), it is approved in Russia as an anxiolytic and nootropic. It exhibits both anxiolytic and cognitive-enhancing properties without sedation or addiction potential.
Nootropic / Antidepressant Peptide
PE-22-28 is a synthetic heptapeptide derived from sortilin propeptide (spadin) that acts as a specific blocker of the TREK-1 potassium channel. TREK-1 deletion in mice produces an antidepressant-resistant phenotype, making TREK-1 blockade a novel antidepressant mechanism. PE-22-28 shows rapid-onset antidepressant-like effects in animal models within 4 days — compared to 2–4 weeks for SSRIs. It is an early-stage research compound.
Neuroprotective Peptide Complex
Cerebrolysin is a porcine brain-derived peptide preparation containing low-molecular-weight neuropeptides and free amino acids that mimic endogenous neurotrophic factors. It is approved in over 50 countries (not the US) for stroke recovery, traumatic brain injury, and dementia. It is one of the most widely prescribed neuroprotective agents globally, with a substantial clinical trial database.
Disclaimer: This content is for educational and informational purposes only and does not constitute medical advice. Always consult with a licensed healthcare provider before starting, stopping, or modifying any peptide therapy. PeptideSupplierMatch does not prescribe, sell, or distribute peptides.
Whether you're sourcing peptides for your business or looking for providers near you, we can help.